Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in EAEU is experiencing steady growth due to several factors.
Customer preferences: Patients suffering from cardiovascular diseases are the primary consumers of anti-coagulants. The increasing prevalence of such diseases, along with a growing geriatric population, has resulted in a rise in demand for anti-coagulants. Additionally, the convenience of oral anti-coagulants over injectable ones has led to a shift in consumer preferences towards oral medications.
Trends in the market: Russia is the largest market for anti-coagulants in the EAEU region, accounting for the majority of the revenue. The market is dominated by a few key players who offer both injectable and oral anti-coagulants. The trend towards oral anti-coagulants is expected to continue, with several new oral medications being introduced into the market. Additionally, the use of biosimilars is expected to increase, as they offer a more cost-effective alternative to branded medications.
Local special circumstances: The EAEU region comprises five member states, each with its own regulatory framework. The varying regulatory requirements make it challenging for pharmaceutical companies to introduce new medications into the market. However, the Eurasian Economic Commission (EEC) is working towards harmonizing the regulatory requirements across member states, which is expected to streamline the process of introducing new medications.
Underlying macroeconomic factors: The EAEU region is experiencing steady economic growth, which has resulted in an increase in healthcare spending. The growing middle class in the region has also led to an increase in demand for high-quality healthcare services. Additionally, the region's aging population has resulted in a rise in the prevalence of chronic diseases, such as cardiovascular diseases, which has further fueled the demand for anti-coagulants.In conclusion, the Anti-Coagulants market in EAEU is expected to continue its steady growth due to the increasing prevalence of cardiovascular diseases, the shift towards oral anti-coagulants, and the growing demand for high-quality healthcare services. While the varying regulatory requirements across member states pose a challenge, the harmonization efforts by the EEC are expected to streamline the process of introducing new medications into the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
